The Departments of Neurology and Neurosurgery at Cedars-Sinai highlighted progress against Alzheimer’s disease, Parkinson’s disease, ALS, multiple sclerosis, brain cancer and stroke in their 2023 Annual Report, which also details advancements in spine surgery.
After resolving missing data burdens, the ENGOT-OV16/NOVA (NCT01847274) study data shows no difference in overall survival for platinum-sensitive recurrent ovarian cancer (PSROC) patients who received PARP inhibitor niraparib maintenance therapy (MT) and those who did not. Results from the trial were presented today at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women’s Cancer by Ursula Matulonis, MD, of the Dana-Farber Cancer Institute.
Administering PARP inhibitor (PARPi) olaparib prior to surgical intervention and chemotherapy in ovarian cancer patients – a new approach – is feasible and resulted in favorable surgical options, managed adverse events, and positive health outcomes, according to results from the Neoadjuvant Olaparib Window (NOW) Trial presented today by Shannon Westin, MD et al. at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women’s Cancer.
Researchers have developed a molecule that is, when administered nasally, extremely effective in preventing the disease caused by all known variants of the SARS-CoV-2 virus.
An investigational molecule has been shown to improve kidney function in people with one form of chronic kidney disease in a small phase 2 clinical trial. Martin Pollak, MD, discusses the journey from research question to potential cure.
Staphylococcus aureus, Clostridioides difficile, Candida auris, Drug-resistant Shigella. These bacteria not only have difficult names to pronounce, but they are also difficult to fight off. These bacteria may infect humans and animals, and the infections they cause are harder to treat than those caused by non-resistant bacteria. Antimicrobial resistance is an urgent global public health threat.
The combination of two oral medications has shown positive results in people with prostate cancer, whose disease has spread to other parts of the body. Compared with XTANDI plus placebo, the investigatory combination of TALZENNA and XTANDI demonstrated a statistically significant and clinically meaningful improvement in radiographic progression-free survival.
A recent study published in JAMA demonstrates the effectiveness of a procedure done under the skin, similar to placing a stent, to treat uncontrolled hypertension, or blood pressure that cannot be controlled despite the use of blood pressure control drugs and agents.
Keck Medicine of USC has launched a Phase 2 clinical trial investigating the effectiveness of a new outpatient, nonsurgical endoscopic procedure in stabilizing blood glucose levels for patients.
Researchers from The University of Texas MD Anderson Cancer Center showed that inhibiting menin with revumenib, previously known as SNDX-5613, yielded encouraging responses for advanced acute leukemias with KMT2A rearrangements or mutant NPM1. Findings from the Phase I AUGMENT-101 trial were published today in Nature.
In a study published in the New England Journal of Medicine co-authored by Vibhor Krishna, MD, associate professor of neurosurgery at the UNC School of Medicine, researchers show that a new focused ultrasound treatment improved dyskinesia and motor impairment in patients with Parkinson’s disease.
Um plugue absorvível entregou terapia com células-tronco com poucos efeitos colaterais em pacientes com fístulas perianais de trato único, segundo descoberta de pesquisadores da Mayo Clinic.
Los investigadores de Mayo Clinic descubrieron que un tapón soluble administró terapia con células madre ocasionando pocos efectos secundarios en pacientes con fístulas perianales de un solo trayecto.
توصّل باحثو مايو كلينك إلى إمكانية العلاج بالخلايا الجذعية عبر سدادة قابلة للذوبان لديها آثارٌ جانبية قليلة على المرضى المصابين بالناسور الشرجي أحادي السبيل. النواسير الشرجية هي ممرات مؤلمة بين الأمعاء والجلد، ولا تُشفى عادةً بالرعاية الطبية أو الجراحية القياسية. إن المصابين بداء كْرون أو غيره من حالات التهاب الأمعاء هم الأكثر عرضة لخطر الإصابة بهذه الحالة المرضية.
Hackensack University Medical Center interventional cardiologists are regional leaders in the multicenter national PROTECT IV clinical trial, which is evaluating the effectiveness of a novel treatment for high-risk patients with complex heart disease and reduced heart function who require cardiac catheterization.
The constant evolution of new COVID-19 variants makes it critical for clinicians to have multiple therapies in their arsenal for treating drug-resistant infections. Researchers have now discovered that a new class of oral drugs that acts directly on human cells can inhibit a diverse range of pathogenic SARS-CoV-2 strains. In their newly published study, the team found a novel mechanism through which the gene that expresses angiotensin converting enzyme-2 (ACE-2)—the cellular receptor to which SARS-CoV-2 binds so that it can enter and infect the cell—is turned on.
Treatment with an FDA-approved cannabidiol (CBD) oil product does not lower pain scores after surgical treatment and stent placement for patients with urinary stones, reports a clinical trial in the April issue of The Journal of Urology®, an Official Journal of the American Urological Association (AUA). The journal is published in the Lippincott portfolio by Wolters Kluwer.
Keck Medicine of USC has launched a clinical trial to study the effect of a novel hormone replacement therapy on postmenopausal cardiovascular disease and cognitive decline.
The Patient-Centered Outcomes Research Institute (PCORI) recently awarded researchers at Wake Forest University School of Medicine $10.2 million to study the effectiveness of an individualized model of hemodialysis, a procedure in which the blood is cleaned by a dialysis machine. The project is a collaboration between the School of Medicine, the Renal Research Institute and other health care systems across the country.
In an effort to improve clinical trial diversity, researchers at The Ohio State University Wexner Medical Center and College of Medicine led a study to create solutions to barriers of access, awareness, discrimination and racism and workforce diversity.
Announcement that the Patient-Centered Outcomes Research Institute (PCORI) tapped University Hospitals (UH) as one of 42 health systems nationwide to carry out a pioneering initiative to accelerate the implementation of practice-changing research results in clinical care to improve patients’ outcomes.
Cedars-Sinai has selected Bruce L. Gewertz, MD, the medical center’s surgeon-in-chief, to be the vice dean of Clinical System Development and Faculty Affairs.
Juvenile dermatomyositis, a rare but often severe and chronic systemic autoimmune disease, includes a large number of patients who are treatment resistant, requiring long term immunosuppressive therapy. A small open-label study published in Arthritis and Rheumatology shows promise using a targeted biologic therapy called abatacept to treat such patients.
A team of researchers has discovered a potential therapeutic that can synergize with existing drugs to more effectively kill certain leukemia cells. The authors published their results on Jan. 19 in the journal Molecular & Cellular Proteomics.
A novel compound that has the potential to starve the bacteria that causes tuberculosis – the world’s leading infectious killer after SARS-CoV2 – is entering human clinical trials.
Denovo Biopharma LLC ("Denovo"), a pioneer in applying precision medicine to the development of innovative therapies, set up a gene registry web portal and invites people who suffer from treatment-resistant depression (TRD) to visit www.iMatchDepression.com to help identify whether they or someone they know may be eligible to participate in a biomarker-guided global Phase 2b clinical trial (the "ENLIGHTEN" study).
A clinical trial testing a freeze-dried, temperature-stable experimental tuberculosis (TB) vaccine in healthy adults found that it was safe and stimulated both antibodies and responses from the cellular arm of the immune system.
High-dose anticoagulation can reduce deaths by 30 percent and intubations by 25 percent in hospitalized COVID-19 patients who are not critically ill when compared to the standard treatment, which is low-dose anticoagulation.
The intent of the new Consortium is to help increase access to early phase cancer clinical trials for patients who would otherwise not have the ability to be treated with novel investigational therapeutic interventions.
Ulcerative colitis assessment could be improved after new research shows that an artificial intelligence model could predict flare-ups and complications after reading biopsies.
A dissolvable plug delivered stem cell therapy with few side effects in patients with single tract perianal fistulas, Mayo Clinic researchers discovered. Perianal fistulas are painful tunnels between the intestine and the skin that often do not go away with standard medical or surgical care.
The ERP Biomarker Qualification Consortium announced today the successful completion of a pharma industry-sponsored study to measure the electrophysiologic effects of ketamine on healthy brain function.
A team of researchers from institutions across the United States, including Moffitt Cancer Center, launched a phase 2 clinical trial evaluating a new treatment option for this patient population. Their results, published in The New England Journal of Medicine, show that treating resectable stage 3 and 4 melanoma patients with the immunotherapy drug pembrolizumab both before and after surgery greatly improves outcomes when compared to pembrolizumab given only after surgery.
UC Davis Health researchers have begun a new stem cell clinical trial to treat patients with swallowing problems. The study takes stem cells and injects them into the patient’s tongue.
The UNM Cancer Center will be one of a few sites in the country participating in a clinical trial to expand the application of theranostic treatment to patients with prostate cancer. This type of treatment is currently used at the cancer center for neuroendocrine tumors. The treatment is a two-part process that first injects the molecule attached to a gallium-68 radioactive isotope that can be imaged to illuminate the cancer cells, which makes them easier to see under Positron Emission Tomography, or PET scans.
Nicholas Tatonetti, PhD, an expert in biomedical data science, has joined Cedars-Sinai as the vice chair of Computational Biomedicine and associate director for Computational Oncology at Cedars-Sinai Cancer.
A recent University of Kentucky Markey Cancer Center study suggests a new radiopharmaceutical compound may be a viable treatment option for patients with advanced cervical cancer.
The mural, designed in collaboration with members of organizations in the surrounding urban community, is one part of the The University of Kansas Cancer Center’s broader campaign to increase the participation of minority and underserved populations in clinical trials.
Researchers recently completed a phase 3 clinical trial that assessed the efficacy and safety of two different classes of oral agents for the treatment of type 2 diabetes in young people aged 10-17 years.
Patients with Parkinson’s disease achieved a significant improvement in their tremors, mobility, and other physical symptoms after having a minimally invasive procedure involving focused ultrasound, according to a new study today published in the New England Journal of Medicine.
Researchers at the Johns Hopkins Kimmel Cancer Center completed what is believed to be the first phase I trial of intravenous Helixor M in the U.S. aimed at determining dosing for subsequent clinical trials and to evaluate safety.
Leqembi, Recientemente Aprobado por la FDA, Muestra un Beneficio Potencial para los Pacientes con Enfermedad en Etapa Temprana, pero la Disponibilidad Llevará tiempo, Comenta Experta de Cedars-Sinai
Um grupo de trabalho de especialistas reformulou o que é considerado clinicamente significativo para desacelerar a progressão da doença de Alzheimer durante ensaios clínicos, incluindo o impacto do tratamento ao longo do tempo e a necessidade de terapias combinadas.
Un grupo de trabajo de expertos ha replanteado qué es importante a nivel clínico para retrasar el avance de la enfermedad de Alzheimer durante los ensayos clínicos, incluidas la repercusión del tratamiento a lo largo del tiempo y la necesidad de terapias combinadas.
ROCKVILLE, MD – Women are often underrepresented in cardiac clinical trials—yet they are at least at equally high risk of death due to cardiovascular disease, and at higher risk of developing drug-induced heart complications compared to men. Clinical trials of medicines generally rely on electrocardiograms (EKG) to measure a patient’s heart’s response to a medicine and determine its safety, yet males and females have a number of differences in their heart physiology that are reflected in consistent variations in their EKGs.
Immunotherapy after surgery increased bladder cancer patients’ chance of staying cancer-free compared to patients who received a placebo, according to clinical trial results shared in a late-breaking oral presentation at the American Society of Clinical Oncology (ASCO) 2023 Genitourinary Cancers Symposium in February.
Delray Medical Center is the first hospital in Florida to treat an Alzheimer’s disease patient using non-invasive focused ultrasound technology as part of a groundbreaking study being conducted in collaboration with FAU’s Institute for Human Health and Disease Intervention (I-Health). In the FDA-approved clinical trial, focused ultrasound technology is used to disrupt the blood-brain barrier in participating Alzheimer’s patients.
Every day for six weeks, Neil Wank, a 26-year Los Angeles Police Department veteran who in December was diagnosed with an aggressive type of brain cancer called glioblastoma, was escorted down the long hallway leading to the Cedars-Sinai Cancer radiation therapy facility by his wife, Nikki, and 10 to 20 of his fellow officers.
Jaime Merchán, M.D., is the new Translational and Clinical Oncology Research Program co-leader at Sylvester Comprehensive Cancer Center, part of UHealth – University of Miami Health System.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right
